Domainex, a contract research organization, announced a collaboration with Sigma-Aldrich to advance the study of epigenetic proteins involved in cancer and stem cell biology. Through the collaboration, Domainex will use its protein expression technology to produce domains of epigenetic proteins to develop biochemical assays, while Sigma-Aldrich will use the proteins to develop monoclonal antibodies. These tools will help researchers study the function of these important proteins. Funding from the UK Technology Strategy Board will support the work.
Domainex Ark Press Release June 2009 Finaldikheidi
Domainex Ltd and Ark Therapeutics have extended their drug discovery agreement. Domainex will continue providing hit-finding and lead optimization services for Ark's therapeutic targets. The companies have worked together successfully for years, combining Domainex's drug design expertise with Ark's disease expertise. Dr. Trevor Perrior of Domainex commented that their collaboration has already achieved breakthroughs against challenging goals, and they look forward to further developing programs to deliver new disease treatments.
Domainex announces the release of the latest version of its LeadBuilder virtual screening platform. LeadBuilder is a proprietary platform developed by Domainex to rapidly identify high-quality small molecule drug leads against novel or difficult protein targets. The latest version includes an expanded database of over six million compounds and software upgrades. LeadBuilder uses target-specific queries to screen compounds and typically achieves hit rates of 1-10%, far better than random high-throughput screening.
Domainex And Pharmidex Announce Drug Discovery Alliancepfallon
Domainex and Pharmidex announce a strategic alliance to provide integrated drug discovery services. The alliance will combine Domainex's expertise in hit identification and medicinal chemistry with Pharmidex's strengths in drug metabolism and pharmacokinetics testing. The companies aim to tackle challenging drug targets and believe the partnership will extend their client bases in the pharmaceutical and biotech sectors.
Domainex has expanded its assay services to include assay development and fragment-based screening using both biochemical and biophysical techniques. It has also launched a new collection of chemical fragments that is more diverse than other commercially available collections. This expansion allows Domainex to screen small molecules against various targets and identify hits using its in silico LeadBuilder technology.
Domainex, a UK-based drug discovery company, won the 2010 Genesis Life Science Innovation and Enterprise Programme of the Year award for its work promoting academic-industry collaborations. Domainex has successfully delivered 3 novel drugs into clinical trials for its clients in the last 4 years using its medicinal chemistry expertise. It currently supports drug discovery consortia with groups like Breakthrough Breast Cancer and St George's University of London.
Domainex, a UK-based drug discovery company, won the 2010 Genesis Life Science Innovation and Enterprise Programme of the Year award for its work promoting academic-industry collaborations. Domainex has successfully delivered 3 novel drugs into clinical trials for its clients in the last 4 years. It currently supports drug discovery consortia with groups like Breakthrough Breast Cancer and St George's University of London.
Domainex, a contract research organization, announced a collaboration with Sigma-Aldrich to advance the study of epigenetic proteins involved in cancer and stem cell biology. Through the collaboration, Domainex will use its protein expression technology to produce domains of epigenetic proteins to develop biochemical assays, while Sigma-Aldrich will use the proteins to develop monoclonal antibodies. These tools will help researchers study the function of these important proteins. Funding from the UK Technology Strategy Board will support the work.
Domainex Ark Press Release June 2009 Finaldikheidi
Domainex Ltd and Ark Therapeutics have extended their drug discovery agreement. Domainex will continue providing hit-finding and lead optimization services for Ark's therapeutic targets. The companies have worked together successfully for years, combining Domainex's drug design expertise with Ark's disease expertise. Dr. Trevor Perrior of Domainex commented that their collaboration has already achieved breakthroughs against challenging goals, and they look forward to further developing programs to deliver new disease treatments.
Domainex announces the release of the latest version of its LeadBuilder virtual screening platform. LeadBuilder is a proprietary platform developed by Domainex to rapidly identify high-quality small molecule drug leads against novel or difficult protein targets. The latest version includes an expanded database of over six million compounds and software upgrades. LeadBuilder uses target-specific queries to screen compounds and typically achieves hit rates of 1-10%, far better than random high-throughput screening.
Domainex And Pharmidex Announce Drug Discovery Alliancepfallon
Domainex and Pharmidex announce a strategic alliance to provide integrated drug discovery services. The alliance will combine Domainex's expertise in hit identification and medicinal chemistry with Pharmidex's strengths in drug metabolism and pharmacokinetics testing. The companies aim to tackle challenging drug targets and believe the partnership will extend their client bases in the pharmaceutical and biotech sectors.
Domainex has expanded its assay services to include assay development and fragment-based screening using both biochemical and biophysical techniques. It has also launched a new collection of chemical fragments that is more diverse than other commercially available collections. This expansion allows Domainex to screen small molecules against various targets and identify hits using its in silico LeadBuilder technology.
Domainex, a UK-based drug discovery company, won the 2010 Genesis Life Science Innovation and Enterprise Programme of the Year award for its work promoting academic-industry collaborations. Domainex has successfully delivered 3 novel drugs into clinical trials for its clients in the last 4 years using its medicinal chemistry expertise. It currently supports drug discovery consortia with groups like Breakthrough Breast Cancer and St George's University of London.
Domainex, a UK-based drug discovery company, won the 2010 Genesis Life Science Innovation and Enterprise Programme of the Year award for its work promoting academic-industry collaborations. Domainex has successfully delivered 3 novel drugs into clinical trials for its clients in the last 4 years. It currently supports drug discovery consortia with groups like Breakthrough Breast Cancer and St George's University of London.
Natural products company Hypha Discovery has signed a deal with Domainex to develop novel oncology drugs. Hypha has identified a pipeline of natural products with activity against tumor cell lines, including the HD148 chemical series inspired by compounds from a tropical mushroom. Domainex will use its drug development platform and medicinal chemistry expertise to optimize the HD148 series and deliver an advanced lead molecule and clinical candidate. Both companies look forward to the collaboration advancing Hypha's oncology programs.
Domainex TSB Funding Awarded For Cancer Programpfallon
Domainex, a UK-based drug discovery company, was awarded a £250,000 grant by the UK's Technology Strategy Board to support development of a new cancer drug. The drug inhibits two protein kinases, TBK1 and IKKε, that are important in cancer cell growth. Initial focus will be on breast and ovarian cancers which have poor survival rates. The funding will allow Domainex to hire scientists and advance the drug through preclinical testing towards commercialization with a pharmaceutical partner.
Domainex, a biotechnology company, has secured further financing from existing shareholders Longbow Capital and The Capital Fund, as well as new investor Takeda Research Investment. This funding will allow Domainex to advance its internal oncology drug research portfolio and take its novel cancer targets toward corporate collaborations and deals. CEO Eddy Littler welcomed the new investment and said it will help the company further develop its Combinatorial Domain Hunting technology and oncology pipeline over the next few months.
Domainex, a biotechnology company, has secured further financing from existing shareholders Longbow Capital and The Capital Fund as well as new investor Takeda Research Investment. This funding will allow Domainex to advance its internal oncology drug research portfolio and take its novel cancer targets toward corporate collaborations and deals. CEO Eddy Littler welcomed the new investment and said it will help the company further develop its Combinatorial Domain Hunting technology and oncology pipeline over the next few months.
Domainex, a contract research and drug discovery company, is seeking experienced medicinal chemists for positions in Cambridge, UK. Ideal candidates will have a chemistry PhD, industry experience in drug design, organic synthesis, and communication skills. The positions offer the opportunity to work with a highly experienced team in state-of-the-art laboratories located in Cambridge's biotechnology cluster on all aspects of drug discovery from hit identification to clinical candidates.
Horizon Discovery and Domainex Ltd have collaborated to support Domainex's TBK1/IKKε oncology research program. Under the agreement, Horizon will use its isogenic cell lines that model cancer mutations to profile Domainex's lead compounds. This will help identify which patient subgroups will respond and guide medicinal chemistry optimization. The collaboration will help efficiently develop a drug for this cancer target.
Clinical Trial Logistics & Supply (2011) FbFateja
This document provides information about an upcoming clinical trial logistics and supply conference to be held in London on September 29-30, 2011. It lists key speakers from various pharmaceutical companies that will discuss topics like predictive drug supply modelling, bioequivalence studies, drug pooling strategies, quality assurance, and managing clinical trials in Eastern Europe. The document also provides details about sponsoring, exhibiting, and submitting poster presentations at the conference.
KLSC is a life sciences investment company fully owned by the Kuwait Investment Authority and National Technology Enterprises Company. It aims to advance healthcare in Kuwait and the Gulf region by investing in innovative companies and technologies, and establishing the first healthcare academy in the GCC to provide education and training. KLSC has investments in companies like Newbridge Pharmaceuticals and Clinart MENA that are addressing unmet medical needs, and works with partners around the world in areas like medical technology, diagnostics and pharmaceuticals.
Domainex Press Release For Wt Mpr Final Version (2) (2)dikheidi
Domainex, an innovative biopharmaceutical company, announced a collaboration with St George’s Hospital Medical School and the University of Manchester on a new asthma treatment. Domainex will provide over £1.5 million in services like lead optimization over two years to help develop a drug candidate for clinical trials. Researchers discovered compounds that inhibit an enzyme triggering asthma. The universities received a £4 million grant to advance the research. The collaboration will use Domainex's virtual screening and medicinal chemistry expertise to accelerate developing an anti-asthma drug.
This document announces the 11th Annual Biosimilars UK conference taking place October 29-31, 2012 in London. It will bring together major pharmaceutical companies, regulatory bodies, CROs, CMOs, and law firms to discuss strategies for competing in the complex biosimilars market. Key topics will include the latest regulatory guidelines, financial viability, patent strategies, approval pathways, legal issues, preclinical/clinical challenges, the roles of the US and European markets, pricing/reimbursement, and pharmacovigilance. The goal is to help participants maximize opportunities in this changing landscape. Major sponsors include Merck Millipore and United BioSource Corporation.
Domainex, an innovative biopharmaceutical company, announced a collaboration with St George’s Hospital Medical School and the University of Manchester on a new asthma treatment. Domainex will provide over £1.5 million in services like lead optimization over two years to help develop a drug candidate for clinical trials. Researchers discovered compounds that inhibit an enzyme triggering asthma. The universities received a £4 million grant to advance the research. The collaboration will use Domainex's expertise in computational chemistry to accelerate developing an anti-asthma drug.
Eurand, a specialty pharmaceutical company, has hired Robert Becker as their new Chief Research Officer to oversee global research and development. Becker has nearly 25 years of experience in the pharmaceutical industry. As CRO, he will consolidate Eurand's core drug delivery technologies and identify new formulation approaches to advance the company's position in drug development partnerships and as an integrated pharmaceutical company. The new role aims to make R&D a greater contributor to Eurand's success and growth by leveraging their innovation in drug delivery to support their expanding proprietary product pipeline.
This document provides information about various companies pitching at a conference on Stratified Medicine opportunities for business. It lists 12 companies and organizations, including 3di Consulting, Enterprise Europe Network, GfK Bridgehead, Harrison Goddard Foote, iFormulate, In Silico Genesis, Maddison Product Design, Platelet Solutions, Source Bioscience, TouchApp, Trio Venture Management, and University of Leeds. It also includes brief descriptions and contact information for some of these companies.
Development of an Solid tumors ‐ Grenoble Institute of Assistant 2010‐2012: €500K Preclinical POC 28
intelligent robotic assistant for Neurosciences (GIN) Medical, €250K CLARA ongoing
minimally invasive surgery ‐ Joseph Fourier University Grenoble €250K Assistant
(UJF) Medical
Nano‐HIFU: Nanoparticles for Liver, pancreas ‐ LabTAU, Inserm, Lyon Nano‐H, Saint‐ 2010‐2013: €1.2M Preclinical POC 29
High Intensity Focused Ultrasound metastases
The document describes Aptuit INDiGO's accelerated drug development program. It offers integrated services to help clients advance molecules from candidate selection to clinical trials in as few as 52 weeks. This is significantly faster than the industry average of 122 weeks. Aptuit's program provides world-class expertise across preclinical and clinical development, API manufacturing, and regulatory submission preparation to streamline the process. It aims to reduce costs and development time while improving data quality for clients.
As of my last knowledge update in September 2021, the list of the top Contract Research Organizations (CROs) can vary depending on factors such as revenue, services offered, therapeutic areas of expertise, and global presence. The following list includes some of the prominent CROs based on their reputation, scale, and contributions to the clinical research industry:
IQVIA (formerly QuintilesIMS):
IQVIA is one of the largest CROs in the world, offering a wide range of services including clinical development, real-world evidence solutions, commercialization services, and consulting. They have a vast global network and expertise across various therapeutic areas.
PPD (Pharmaceutical Product Development):
PPD is known for its comprehensive clinical trial services, laboratory services, and real-world evidence solutions. They have a strong global presence and experience in managing trials of varying complexity.
Covance:
Covance, a subsidiary of LabCorp, is known for its extensive portfolio of drug development services including clinical development, central laboratory services, and market access solutions. They have experience in a broad range of therapeutic areas.
Syneos Health:
Syneos Health offers integrated solutions across clinical development, commercialization, and real-world evidence. They focus on helping clients navigate the entire drug development journey.
ICON:
ICON provides a variety of clinical research services, including consulting, clinical trial execution, laboratory services, and outcomes research. They have expertise in a wide array of therapeutic areas.
Parexel:
Parexel offers services ranging from clinical research and regulatory consulting to market access and commercialization. They are known for their global reach and innovative approach to clinical trials.
WuXi AppTec:
WuXi AppTec is a global company that provides a wide range of R&D services, including preclinical and clinical development, manufacturing, and regulatory services.
Medpace:
Medpace is known for its focused and customized approach to clinical trial management, particularly in the area of complex and specialized studies.
Celerion:
Celerion specializes in early-stage clinical research, with a focus on providing solutions for both small and large molecules.
Charles River Laboratories:
While Charles River Laboratories primarily focuses on preclinical research, they also offer a range of early-stage clinical development services.
The Centre for Business Innovation (CfBI) is expanding its consortia programs in 2012 to help companies collaborate and gain competitive advantages. Key highlights include:
1) The Microfluidics consortium (MF-3) will extend to the US, hosted by Johnson & Johnson, while the Nano-Carbon-Enabled Materials Consortium (NCEM-1) will launch in Spring 2012.
2) The Open Innovation Practitioners consortium (OI-3) will focus on health/wellness and new media, benefiting members through benchmarking, testing ideas, and engaging stakeholders.
3) New consortia on corporate venturing, new media, and flow chemistry are planned for Fall 2012
Natural products company Hypha Discovery has signed a deal with Domainex to develop novel oncology drugs. Hypha has identified a pipeline of natural products with activity against tumor cell lines, including the HD148 chemical series inspired by compounds from a tropical mushroom. Domainex will use its drug development platform and medicinal chemistry expertise to optimize the HD148 series and deliver an advanced lead molecule and clinical candidate. Both companies look forward to the collaboration advancing Hypha's oncology programs.
Domainex TSB Funding Awarded For Cancer Programpfallon
Domainex, a UK-based drug discovery company, was awarded a £250,000 grant by the UK's Technology Strategy Board to support development of a new cancer drug. The drug inhibits two protein kinases, TBK1 and IKKε, that are important in cancer cell growth. Initial focus will be on breast and ovarian cancers which have poor survival rates. The funding will allow Domainex to hire scientists and advance the drug through preclinical testing towards commercialization with a pharmaceutical partner.
Domainex, a biotechnology company, has secured further financing from existing shareholders Longbow Capital and The Capital Fund, as well as new investor Takeda Research Investment. This funding will allow Domainex to advance its internal oncology drug research portfolio and take its novel cancer targets toward corporate collaborations and deals. CEO Eddy Littler welcomed the new investment and said it will help the company further develop its Combinatorial Domain Hunting technology and oncology pipeline over the next few months.
Domainex, a biotechnology company, has secured further financing from existing shareholders Longbow Capital and The Capital Fund as well as new investor Takeda Research Investment. This funding will allow Domainex to advance its internal oncology drug research portfolio and take its novel cancer targets toward corporate collaborations and deals. CEO Eddy Littler welcomed the new investment and said it will help the company further develop its Combinatorial Domain Hunting technology and oncology pipeline over the next few months.
Domainex, a contract research and drug discovery company, is seeking experienced medicinal chemists for positions in Cambridge, UK. Ideal candidates will have a chemistry PhD, industry experience in drug design, organic synthesis, and communication skills. The positions offer the opportunity to work with a highly experienced team in state-of-the-art laboratories located in Cambridge's biotechnology cluster on all aspects of drug discovery from hit identification to clinical candidates.
Horizon Discovery and Domainex Ltd have collaborated to support Domainex's TBK1/IKKε oncology research program. Under the agreement, Horizon will use its isogenic cell lines that model cancer mutations to profile Domainex's lead compounds. This will help identify which patient subgroups will respond and guide medicinal chemistry optimization. The collaboration will help efficiently develop a drug for this cancer target.
Clinical Trial Logistics & Supply (2011) FbFateja
This document provides information about an upcoming clinical trial logistics and supply conference to be held in London on September 29-30, 2011. It lists key speakers from various pharmaceutical companies that will discuss topics like predictive drug supply modelling, bioequivalence studies, drug pooling strategies, quality assurance, and managing clinical trials in Eastern Europe. The document also provides details about sponsoring, exhibiting, and submitting poster presentations at the conference.
KLSC is a life sciences investment company fully owned by the Kuwait Investment Authority and National Technology Enterprises Company. It aims to advance healthcare in Kuwait and the Gulf region by investing in innovative companies and technologies, and establishing the first healthcare academy in the GCC to provide education and training. KLSC has investments in companies like Newbridge Pharmaceuticals and Clinart MENA that are addressing unmet medical needs, and works with partners around the world in areas like medical technology, diagnostics and pharmaceuticals.
Domainex Press Release For Wt Mpr Final Version (2) (2)dikheidi
Domainex, an innovative biopharmaceutical company, announced a collaboration with St George’s Hospital Medical School and the University of Manchester on a new asthma treatment. Domainex will provide over £1.5 million in services like lead optimization over two years to help develop a drug candidate for clinical trials. Researchers discovered compounds that inhibit an enzyme triggering asthma. The universities received a £4 million grant to advance the research. The collaboration will use Domainex's virtual screening and medicinal chemistry expertise to accelerate developing an anti-asthma drug.
This document announces the 11th Annual Biosimilars UK conference taking place October 29-31, 2012 in London. It will bring together major pharmaceutical companies, regulatory bodies, CROs, CMOs, and law firms to discuss strategies for competing in the complex biosimilars market. Key topics will include the latest regulatory guidelines, financial viability, patent strategies, approval pathways, legal issues, preclinical/clinical challenges, the roles of the US and European markets, pricing/reimbursement, and pharmacovigilance. The goal is to help participants maximize opportunities in this changing landscape. Major sponsors include Merck Millipore and United BioSource Corporation.
Domainex, an innovative biopharmaceutical company, announced a collaboration with St George’s Hospital Medical School and the University of Manchester on a new asthma treatment. Domainex will provide over £1.5 million in services like lead optimization over two years to help develop a drug candidate for clinical trials. Researchers discovered compounds that inhibit an enzyme triggering asthma. The universities received a £4 million grant to advance the research. The collaboration will use Domainex's expertise in computational chemistry to accelerate developing an anti-asthma drug.
Eurand, a specialty pharmaceutical company, has hired Robert Becker as their new Chief Research Officer to oversee global research and development. Becker has nearly 25 years of experience in the pharmaceutical industry. As CRO, he will consolidate Eurand's core drug delivery technologies and identify new formulation approaches to advance the company's position in drug development partnerships and as an integrated pharmaceutical company. The new role aims to make R&D a greater contributor to Eurand's success and growth by leveraging their innovation in drug delivery to support their expanding proprietary product pipeline.
This document provides information about various companies pitching at a conference on Stratified Medicine opportunities for business. It lists 12 companies and organizations, including 3di Consulting, Enterprise Europe Network, GfK Bridgehead, Harrison Goddard Foote, iFormulate, In Silico Genesis, Maddison Product Design, Platelet Solutions, Source Bioscience, TouchApp, Trio Venture Management, and University of Leeds. It also includes brief descriptions and contact information for some of these companies.
Development of an Solid tumors ‐ Grenoble Institute of Assistant 2010‐2012: €500K Preclinical POC 28
intelligent robotic assistant for Neurosciences (GIN) Medical, €250K CLARA ongoing
minimally invasive surgery ‐ Joseph Fourier University Grenoble €250K Assistant
(UJF) Medical
Nano‐HIFU: Nanoparticles for Liver, pancreas ‐ LabTAU, Inserm, Lyon Nano‐H, Saint‐ 2010‐2013: €1.2M Preclinical POC 29
High Intensity Focused Ultrasound metastases
The document describes Aptuit INDiGO's accelerated drug development program. It offers integrated services to help clients advance molecules from candidate selection to clinical trials in as few as 52 weeks. This is significantly faster than the industry average of 122 weeks. Aptuit's program provides world-class expertise across preclinical and clinical development, API manufacturing, and regulatory submission preparation to streamline the process. It aims to reduce costs and development time while improving data quality for clients.
As of my last knowledge update in September 2021, the list of the top Contract Research Organizations (CROs) can vary depending on factors such as revenue, services offered, therapeutic areas of expertise, and global presence. The following list includes some of the prominent CROs based on their reputation, scale, and contributions to the clinical research industry:
IQVIA (formerly QuintilesIMS):
IQVIA is one of the largest CROs in the world, offering a wide range of services including clinical development, real-world evidence solutions, commercialization services, and consulting. They have a vast global network and expertise across various therapeutic areas.
PPD (Pharmaceutical Product Development):
PPD is known for its comprehensive clinical trial services, laboratory services, and real-world evidence solutions. They have a strong global presence and experience in managing trials of varying complexity.
Covance:
Covance, a subsidiary of LabCorp, is known for its extensive portfolio of drug development services including clinical development, central laboratory services, and market access solutions. They have experience in a broad range of therapeutic areas.
Syneos Health:
Syneos Health offers integrated solutions across clinical development, commercialization, and real-world evidence. They focus on helping clients navigate the entire drug development journey.
ICON:
ICON provides a variety of clinical research services, including consulting, clinical trial execution, laboratory services, and outcomes research. They have expertise in a wide array of therapeutic areas.
Parexel:
Parexel offers services ranging from clinical research and regulatory consulting to market access and commercialization. They are known for their global reach and innovative approach to clinical trials.
WuXi AppTec:
WuXi AppTec is a global company that provides a wide range of R&D services, including preclinical and clinical development, manufacturing, and regulatory services.
Medpace:
Medpace is known for its focused and customized approach to clinical trial management, particularly in the area of complex and specialized studies.
Celerion:
Celerion specializes in early-stage clinical research, with a focus on providing solutions for both small and large molecules.
Charles River Laboratories:
While Charles River Laboratories primarily focuses on preclinical research, they also offer a range of early-stage clinical development services.
The Centre for Business Innovation (CfBI) is expanding its consortia programs in 2012 to help companies collaborate and gain competitive advantages. Key highlights include:
1) The Microfluidics consortium (MF-3) will extend to the US, hosted by Johnson & Johnson, while the Nano-Carbon-Enabled Materials Consortium (NCEM-1) will launch in Spring 2012.
2) The Open Innovation Practitioners consortium (OI-3) will focus on health/wellness and new media, benefiting members through benchmarking, testing ideas, and engaging stakeholders.
3) New consortia on corporate venturing, new media, and flow chemistry are planned for Fall 2012
1. Press Release
Domainex announces the appointment of Joanne McCudden as Head of
Business Development.
Cambridge, UK, 20th September 2010.
Domainex Ltd announces the appointment of Dr Joanne McCudden as Head
of Business Development. Joanne joins the Company with a wealth of
experience in the biotech sector having held business development positions
at Cobra Biomanufacturing PLC and, more recently, with SynCo Bio Partners
where she was the Director of Sales and Marketing.
Dr McCudden commented “Domainex offers high-quality, added-value, drug
discovery services to the global biotechnology and pharma marketplaces. Its
technical expertise is superb: shown by the success realised on behalf of its
clients and with its own internal drug research portfolio. I am very pleased to
join Domainex, especially at this exciting time of growth. It is a pivotal moment
for the business, and I look forward to helping to expand its client base, whilst
supporting the outlicensing effort for the internal programmes.”
Dr Eddy Littler CEO of Domainex said “Domainex is entering a new phase in
its development. Our service division is undergoing a significant expansion
with a number of new contracts, and our drug discovery division has
advanced its first project - on the kinase targets IKKe and TBK1 - to a point
where we will seek to outlicense the project during 2011. We are delighted
that Joanne is joining Domainex in order to spearhead our future Business
Development activities”.
- ENDS -
2. Editors Notes:
About Domainex
• Domainex uses unique and proprietary technologies to resolve
common bottlenecks facing the pharmaceutical and biotechnology
industries in the post-genomic era. Major discovery 'gaps' exist
between the vast amount of genomic information that is now available,
the accessibility of the corresponding proteins for use in target
validation and drug discovery, and the identification of robust hits in a
cost effective manner. Founded in 2002, Domainex is a privately
owned company with laboratories in Cambridge, England, and offices
in the London Bioscience Innovation Centre.
• Domainex has developed a number of platform technologies
specifically aimed at enabling biotech or university groups who have
exciting new drug targets. Its Combinatorial Domain Hunting (CDH)
technology will deliver protein constructs that are soluble, stable, and
produced in high-yield - thereby opening up the path to high throughput
screening, structural biology, or antibody production.
• Domainex has also developed LeadBuilder - a virtual screening
approach for targets which is specifically aimed at identifying hit
molecules that are ideally suited for further development.
• The experienced medicinal chemistry team has a proven track record
in supporting biotech or university groups by providing expertise to take
hit compounds through lead optimisation and on to candidate selection.
Several compounds arising from these collaborations are currently in
clinical evaluation.
• Domainex works with clients on a fee-for-service basis. In 2010, the
company secured investment to advance its own internal drug
discovery pipeline based upon a number of targets in oncology. These
targets are being progressed using Domainex’s platform technologies.
• For more information see: www.domainex.co.uk .
2